Longeveron Secures Patent in China for Stem Cell Potency Assays
Longeveron announced that the China National Intellectual Property Administration has granted a patent covering potency assay methods for assessing human mesenchymal stem cells derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, an amniotic membrane, an umbilical cord or a placenta or differentiated from induced pluripotent stem cells. Potency assays are a crucial element for approved cell-based therapy products.
